Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function

Simone Mantesso†, Dirk Geerts, Jan Spanholtz and Lucia Kučerová

Research and Development, Glycostem Therapeutics, Oss, Netherlands

Natural Killer (NK) cells are unique immune cells capable of efficient killing of infected and transformed cells. Indeed, NK cell-based therapies induced response against hematological malignancies in the absence of adverse toxicity in clinical trials. Nevertheless, adoptive NK cell therapies are reported to have exhibited poor outcome against many solid tumors. This can be mainly attributed to limited infiltration of NK cells into solid tumors, downregulation of target antigens on the tumor cells, or suppression by the chemokines and secreted factors present within the tumor microenvironment. Several methods for genetic engineering of NK cells were established and consistently improved over the last decade, leading to the generation of novel NK cell products with enhanced anti-tumor activity and improved tumor homing. New generations of engineered NK cells are developed to better target refractory tumors and/or to overcome inhibitory tumor microenvironment. This review summarizes recent improvements in approaches to NK cell genetic engineering and strategies implemented to enhance NK cell effector functions.

Keywords: natural killer cells, tumor, genetic engineering, transduction, transfection, chimeric antigen receptor-natural killer cells, activating receptors, inhibitory receptors

INTRODUCTION

Natural killer (NK) cells are part of the innate immune system. Discovered more than 40 years ago, they kill virus-infected cells, counteract tumor formation and initiate innate immune responses (1). Lower NK cell counts and reduced cytotoxicity are associated with higher cancer risks (2, 3), as NK cells kill aberrant somatic cells with downregulated major histocompatibility complex class I (MHC-I) molecules that escape T-cell scrutiny (1). Immunotherapy is a powerful biological therapy for boosting the patient’s immune system, helping it to fight cancer off. Currently, immunotherapy options include compounds like monoclonal antibodies, cancer vaccines, and checkpoint inhibitors, and more recently cellular products like T cells, dendritic cells or NK cells. Early results showed that NK cells can be a safer alternative over T cells due to reduced side effects. Currently however, NK cell ex vivo expansion technologies are laborious, and their persistence in vivo is limited. Genetic engineering is a valuable tool to overcome these limitations and improve NK cells target specificity and cytotoxicity. NK cells were difficult to genetically modify but recently, NK cell engineering has become efficient and reproducible. This review will summarize recent improvements of NK cell engineering and discuss their use in increasing antitumor efficacy and in vivo persistence through improved tumor homing, and higher target specificity and cytotoxicity (Figure 1).
FUNCTIONALITY AND MECHANISM OF ACTION OF NATURAL KILLER CELLS

NK cells represent the main innate lymphocyte cell type. They mediate both anti-tumor and anti-viral responses. Only anti-tumor effects will be the subject of this review. NK cells are generally classified as CD56+CD3- lymphoid cells and further subdivided into two major subpopulations based on CD56 and CD16 receptor surface expression: CD56dimCD16bright and CD56brightCD16dim cells (4, 5). Circulating CD56dimCD16bright NK cells are quiescent but become highly cytotoxic upon recognition of target cells, CD56brightCD16dim cells, that reside in secondary lymphoid tissues, constitutively produce cytokines (6, 7). NK cells killing ability is tightly regulated by a wide range of inhibitory and activating receptors (1). The most prominent inhibitory receptors are the inhibitory killer-cell immunoglobulin-like receptors (KIRs), that bind polymorphic classical MHC-I molecules (HLA-ABC), universally expressed on healthy cells (8). A major role is also played by the inhibitory heterodimer receptor CD94-NKG2A that binds the non-classical MHC-I molecule HLA-E (9, 10). NK cell activating receptors comprise DNAM-1, NKG2D, CD94/NKG2C, CD94/NKG2E, TGF-β receptors.
natural cytotoxicity receptors (NCRs) like NKp30, NKp44, NKp46, and CD16 (11–14) and activating KIRs. All these recognize specific ligands on the surface of target cells: the CD94/NKG2C and CD94/NKG2E heterodimers recognize HLA-E molecules, the NKG2D receptor recognizes the MHC class-I-chain related proteins A and B (MICA and MICB) and UL16 binding proteins (ULBPs), and DNAM-1 recognizes nectin-2 (CD112) and nectin-like proteins (15, 16). Upon activation, NK cells release lytic granules containing perforin and granzyme B within the immunological synapse to kill target cells (17). NK cells can also exert antibody-dependent cell cytotoxicity (ADCC) by recognizing antibody-coated cells through the low-affinity receptor for the Fc portion of IgG1 antibodies (FcγRIIIa or CD16). Activated NK cells also secrete soluble factors like tumor necrosis factor α (TNF-α), TNF-related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL) to trigger apoptosis in target cells (18). And finally, they secrete interferon γ (IFN-γ) (19), growth factors (GM-CSF), immunoregulatory cytokines (IL-15, IL-10, and IL-13) and chemokines (20, 21). These cytokines modulate both innate and adaptive immune responses, such as dendritic cell (DC) maturation and CD4+ to Th1 T cell differentiation, respectively (22–24).

**TUMOR CELLS ESCAPE NK CELLS SURVEILLANCE**

NK cells prevent tumor formation and metastases (25). Blood NK cell counts positively correlate with lower risk for cancer development (2), whereas higher tumor tissue NK cell infiltration correlates with improved treatment outcomes (26, 27). This antitumor effect has been comprehensively summarized elsewhere recently (21). However, solid tumors develop escape mechanisms to avoid NK cell recognition (28). They can upregulate MHC-I expression and thereby engage inhibitory NK cell receptors. For example, HLA-E upregulation increases engagement of the NKG2A/CD94 heterodimer in IFN-γ-stimulated ovarian cancer cell lines, dampening NK cell activity (29). Another resistance mechanism involves the downregulation or shedding of NK cell activating receptor ligands (30). Recently, it was found that NK cells express the immune checkpoint inhibitor PD-1 and that their cytotoxic activity is reduced upon PD-1 engagement in PD-L1 expressing tumors (31). Another recognized key player for tumor cell survival and immune system escape is the tumor microenvironment (TME). The TME comprises tumor-associated non-malignant cells and extracellular matrix components. It secretes suppressive cytokines, like transforming growth factor (TGF)–β (32) and IL-10 (33), or suppressive factors like prostaglandin E2 (PGE2) and adenosine (34, 35) that prevent NK cell mobilization and target tissue infiltration. Most of these immunosuppressive factors are secreted by tumor-associated cells, mainly regulatory T cells (T-regs) (36), M2 macrophages and myeloid-derived suppressor cells (MDSCs) (37). Additionally, the TME can be hypoxic by the tumor’s high metabolism and poor vascularization, impairing NK cells cytotoxic activity (38). In conjunction, hypoxia favors the selection of the phenotypically most aggressive clones, and tumors become capable of sustained proliferation and metastatic potential that can no longer be controlled by NK cell action (39). Therefore, novel approaches for sustaining NK cells antitumor action are crucial for the development of effective tumor therapy.

**NK CELL GENETIC MODIFICATION FOR SUSTAINED FUNCTIONALITY IN CANCER IMMUNOTHERAPY**

Several clinical trials have confirmed the safety profile and efficacy of adoptive NK cells as treatment for hematological malignancies (21). NK cells do not mediate severe toxicities like graft-versus host disease (GVHD) or cytokine release syndrome (CRS) and, therefore, do not require stringent HLA matching (40, 41), the bane of T cell therapies. Consequently, NK cells derived from a single donor can be used to treat several patients. This “off-the-shelf application” dramatically improves therapy access and reduces production times and costs. The trials however also highlighted a relatively limited effectiveness against solid tumors (21). This is caused by low tumor homing and infiltration, short in vivo persistence and impaired NK cell activity in the cancer patients, this by tumor antigen downregulation and the immunosuppressive TME (28). To overcome these drawbacks, genetic modifications of NK cells has been suggested, and will be discussed in detail in this study. Resting primary NK cells from peripheral blood (PB) or umbilical cord blood (UCB) are difficult to engineer by commonly used approaches, like lentivirus, as low transduction efficiencies were always reported (42). Reduced transduction efficiency rates may be explained by the strong antiviral mechanisms NK cells possess (43). Lentiviral transduction can activate innate immune receptor signaling and trigger NK cell apoptosis. Retrovirus showed higher transduction rates in NK cell lines (especially NK-92) or ex vivo activated and expanded NK cells, mostly PB-NK cells (44) (Table 1). Standard retroviral transduction methods (γ-retroviruses), though not known to alter NK cell phenotype and function (45), carry the risk of insertional mutagenesis due to their preference of inserting into active gene promoters, and thereby represent a yet unresolved safety concern, especially if high multiplicity of infection (MOI) rates are used. Besides, NK cell viability after retroviral transduction has been seldom reported and data are scarce. On the other hand, lentiviral transduction methods do not require actively dividing cells, conversely to standard retroviral systems (57). All viral systems are limited in insert size (< 10 kb). All in all, transduction efficiencies remain variable, depending on the NK cell source and MOI (which is seldom reported), and sufficient transduction may require either multiple transductions rounds or post-transduction cell enrichment (Table 1). Alternatively, high transgene expression levels in both primary and ex vivo expanded NK cells (58, 59), can be
TABLE 1 | Genetic modification of NK cells with viral methods.

| NK source | Pre-stimulation | Method | Envelope | Construct | Target(s) | MOI | Efficiency | Reference |
|-----------|-----------------|--------|----------|-----------|-----------|-----|------------|-----------|
| PB        | Co-culture with K562-mbIL15-41BBL and IL-2 10 IU/ml | Retrovirus | RD114 | CD19-2B4- CD3ζ CAR | CD19 | n.r. | 43%–98% | (44) |
| PB        | Co-culture with K562-mbIL15-41BBL and IL-2 10 IU/ml | Retrovirus | RD114 | CD19-2B4- CD3ζ CAR | CD19 | n.r. | 24% ± 7.4% | (45) |
| PB        | Co-culture with K562-mbIL15-41BBL and IL-2 10 IU/ml | Retrovirus | RD114 | Membrane-bound IL-15 | none | n.r. | 40%–63% | (46) |
| PB        | Co-culture with K562-mbIL15-41BBL and IL-2 100 IU/ml | Retrovirus | RD114 | hTERT | none | n.r. | 51%–65% | (47) |
| PB        | Co-culture with EBV-LVL | Retrovirus | gp100-specific T cell receptor | NGFR CXCR2 | none | n.r. | 26%–93% | (48) |
| PB        | Co-culture with K562-mbIL15-41BBL and IL-2 10 IU/ml | Retrovirus | Murine stem cell virus | NKG2D-DAP10- CD3ζ | MICA, MICB, ULBP | NKG2A | n.r. | 28% | (49) |
| PB        | Co-culture with K562-mbIL15-41BBL and IL-2 400 IU/ml | Retrovirus | Murine stem cell virus | Anti-NG2A PEBL | NKG2A | n.r. | 49%–82% | (50) |
| UCB       | IL-15 10 ng/ml | Retrovirus | RD114 | Dominant negative TGF-β receptor (NKA) | TGF-β | n.r. | 61%–88% | (51) |
| UCB       | IL-15 100 IU/ml, IL-15 15 ng/ml | Retrovirus | RD114 | Anti-NG2A | TGF-β | n.r. | 43% ± 27% | (52) |
| PB        | IL-12 50 ng/ml | Lentivirus | VSV-G | αβ retrovirus | NKG2A | 10 | 50% ± 20% | (53) |
| PB        | IL-15 10 ng/ml | Lentivirus | VSV-G | αCD19-CD28-CD3ζ CAR | CD19 | 5–10 | 0%–34% | (42) |
| PB        | IL-2 500 IU/ml | Lentivirus | VSV-G | αCD19-4-1BB-CD3ζ CAR | CD19 | 10 | 41% | (54) |
| PB        | IL-15 10 ng/ml | Lentivirus | VSV-G | eGFP | CD19 | 10 | 70% | (54) |
| PB        | IL-2 500 IU/ml | Lentivirus | VSV-G | eGFP | CD19 | 0.1–10 | <3% | (55) |
| CD34+ HSC from UCB | Quiescent | Lentivirus | VSV-G | eGFP | None | 10 | 0% < 5% | (55) |
| NK-92     | IL-2 50 IU/ml | Lentivirus | VSV-G | IL-15 and eGFP | None | n.r. | 4% (eGFP) | (56) |

Studies based on NK cells lines other than NK-92 have not been reported in this table, as they have not been employed in clinical trials yet. Studies where the transduction efficiency was not reported, or post-transduction enrichment/selection was performed without mentioning the original transduction efficiency were excluded. RD144, serotype of endogenous feline type C virus; n.r., not reported; DNRiII, dominant negative TGF-β RII; NGFR, Nerve Growth Factor Receptor; PEBL, protein expression blocker.

achieved with transfection methods like electroporation and lipofection, that are not limited in insert size (Table 2). Transgene expression after transfection is however not stable over time, strongly reducing its appeal for clinical applications. Other non-viral genetic integration systems like transposons exist with the advantage to not be limited in insert size. Sleeping Beauty and PiggyBac are the most common and well-characterized transposon systems but have so far mainly been tested in T cells, and NK cell studies are still rare and lack safety data. Alternatively, the CRISPR/Cas9 system has been extensively investigated for targeted engineering, with already some studies in NK cells (65). Although CRISPR/Cas9 can be delivered by both viral and non-viral systems, non-viral delivery of a ribonuclease protein (RNP) complex made up by the Cas9 nuclease and the single guide RNA (sgRNA) is preferred, since it limits off-target effects due to viral DNA integration. However, \textit{ex vivo} non-viral delivery requires optimization, as efficiency is often very limited and viability a concern (61). Of note, CRISPR/Cas9 can be used to efficiently screen effective synthetic constructs electroporated into T cells (66), significantly speeding up the discovery of constructs for reprogramming adoptive NK cell functionality and specificity.

Until recently, these limitations delayed NK cell genetic reprogramming for large scale applications compared to T-cells reprogramming. Novel transduction enhancers (e.g. RetroNectin and vecoutifusin-1) and studies on alternative viral envelopes, mostly genetically modified versions of baboon endogenous retrovirus (BaEV) and RD114 feline retrovirus glycoprotein (42, 54, 55), contributed to improved NK cell transduction efficiency, rekindling the interest in genetic manipulation of NK cells (Table 1). The BaEV envelope consistently displayed efficient NK cell transduction and might replace the standard VSV-G envelope in NK cell applications. NK cells can efficiently be differentiated from CD34+ hematopoietic stem and progenitor cells (HSPCs) (67) derived from UCB, human embryonic stem cells (hESCs), or induced pluripotent stem cells (iPSCs) (68, 69). Both CD34+ HSPCs and iPSCs can be effectively modified with VSV-G, RD114, and BaEV-
pseudotyped lentviruses and then differentiated into mature NK cells, and offer another attractive source to generate modified NK cells (35).

In summary, since integrative genetic modification systems are preferred in clinical settings, retrovirus-based genetic engineering has been the established platform to modify NK cells so far. The γ-retroviral systems are being gradually overtaken by lentiviruses after the discovery of new NK cell-specific envelopes and are set to be the mainstay in NK cell engineering for several years. Studies implementing non-viral strategies have emerged in the last years as well, although they are as of yet mostly limited to pre-clinical settings (Figure 1).

### STRATEGIES TO INCREASE TUMOR-SPECIFIC NK CELL CYTOTOXICITY

#### NK Cells Expressing Chimeric Antigen Receptor

Chimeric antigen receptors (CARs) are antibody-based receptors designed to recognize specific ligands on the surface of target cells. All CAR constructs contain an extracellular antibody single-chain variable fragment (scFvs) fused to a transmembrane region and intracellular immune cell activation domains. The first-generation CAR contained only the intracellular CD3ζ stimulatory domain of the T cell receptor (TCR) as activation domain. The second and third generations include one or two additional co-stimulatory domains, respectively (e.g. 4-1BB and/or CD28). CAR technology was first applied on T cells and although CAR-T cells exhibited strong antitumoral clinical responses, their clinical application is severely curtailed by severe toxicities (GvHD and CRS). This allows only autologous applications for CAR-T cells, which decreases treatment accessibility. In addition, T cells for autologous use are necessarily derived from heavily pre-treated patients, which impinges on their functionality. CAR-NK cells, however, can be derived from allogeneic sources, without apparently causing neither GvHD nor CRS in the recipient, potentially related to their short in vivo persistence and lack of clonal expansion. Off-the-shelf CAR-NK cells can, therefore, have a huge advantage in terms of manufacturing time, costs and accessibility. Besides, allogeneic NK cells are derived from healthy patients and thus retain their normal activity. This allows CAR-NK cells to still exert their anti-tumoral effect in case the CAR expression is decreased or lost, in contrast to CAR-T cells. Only a few CAR-NK phase I/II trials have been started in the last years. Most registered clinical trials employ the NK-92 NK cell line, and the CAR constructs used were based on targets developed for CAR-T cells. This knowledge gap is largely caused by the huge success of anti-CD19 CAR-T cells and the vast amount of clinical data available from CAR-T cell therapies, and as of yet precludes critical assessment of clinal CAR-NK applications. Currently, two CAR-NK cell trials targeting CD19 for leukemia treatment are ongoing. The first one is at the MD Anderson Cancer Centre of the University of Texas (NCT03056339) and is based on UCB-NK cells transduced with a CD19-targeting scFv, interleukin 15 (to enhance NK cells persistence) and an inducible caspase-9 (iC9) suicide gene as a failsafe mechanism. Preliminary results demonstrated that the approach is safe, despite only partial HLA matching between donor and recipient, and potency is high (seven out of 11 patients achieved complete remission) (70). Of note, CAR.19/IL-15/iC9-NK cells were detected at low levels up to 12 months after the beginning of the treatment, whereas they normally disappear within 2 weeks. Unfortunately, no data about exhaustion is reported, and the influence of pre-conditioning treatment could not be established. The second trial (NCT02892695) is led by PersonGen BioTherapeutics (Suzhou, China), and is based on the NK-92 cell line transduced with a

| NK type/source | Pre-stimulation | Method | Construct | Targets | Efficiency | Reference |
|---------------|----------------|--------|-----------|---------|-----------|-----------|
| PB            | Co-culture with K562-miL15-41BBL and IL-2 100 IU/ml (1000 IU/ml 24h before electroporation) | Electroporation | αCD19-4-1BB-CD3ζ CAR | CD19 | 18%-59% | (58) |
| PB            | IL-2 600 IU/ml | Electroporation | αCD19-4-1BB-CD3ζ CAR | CD19 | 40% | (59) |
| PB            | Co-culture with EBV-SMI-LCL and IL-2 500 IU/ml | Electroporation | αCD34, CCR7 and CD16-158V | CCL19-CCL21 | 20% | (60) |
| PB            | IL-2 100 IU/ml | Cas9 RNP nucleofection | SFFV promoter | CD16 | > 80% | n.r. |
| NK-92         | Maintained in Matrigel-coated plate for 5 days before nucleofection | Nucleofection | αMesothelin-2B4-CD3ζ CAR | CD16 | 1.2 % | (61) |
| NK-92         | IL-2 1000 IU/ml | Nucleofection | DNT/RII | TGF-β | 3.5% | (62) |
| NK-92         | IL-2 400 IU/ml | Not specified | NKG2D-DAP10-CD3ζ CAR | MICA, MICB, ULPB | 20% ± 2.6% | n.r. |

N.r., not reported; DNT/RII, dominant negative TGF-β RII.

---

**Figure 1**

**TABLE 2 | Genetic modification of NK cells with non-viral methods.**

| NK type/source | Pre-stimulation | Method | Construct | Targets | Efficiency | Reference |
|---------------|----------------|--------|-----------|---------|-----------|-----------|
| PB            | Co-culture with K562-miL15-41BBL and IL-2 100 IU/ml (1000 IU/ml 24h before electroporation) | Electroporation | αCD19-4-1BB-CD3ζ CAR | CD19 | 18%-59% | (58) |
| PB            | IL-2 600 IU/ml | Electroporation | αCD19-4-1BB-CD3ζ CAR | CD19 | 40% | (59) |
| PB            | Co-culture with EBV-SMI-LCL and IL-2 500 IU/ml | Electroporation | αCD34, CCR7 and CD16-158V | CCL19-CCL21 | 20% | (60) |
| PB            | IL-2 100 IU/ml | Cas9 RNP nucleofection | SFFV promoter | CD16 | > 80% | n.r. |
| NK-92         | Maintained in Matrigel-coated plate for 5 days before nucleofection | Nucleofection | αMesothelin-2B4-CD3ζ CAR | CD16 | 1.2 % | (61) |
| NK-92         | IL-2 1000 IU/ml | Nucleofection | DNT/RII | TGF-β | 3.5% | (62) |
| NK-92         | IL-2 400 IU/ml | Not specified | NKG2D-DAP10-CD3ζ CAR | MICA, MICB, ULPB | 20% ± 2.6% | n.r. |

N.r., not reported; DNT/RII, dominant negative TGF-β RII.
third-generation CAR (4-1BBL-CD28-CD3ζ co-stimulatory domains). A third phase I study targeting CD19 with haplo-identical PBNK cells for B-ALL treatment has been completed (NCT00995137), but no results are available so far. The NK-92 cell line is employed in most of the other phase I/II studies, targeting CD7 (NCT02742727) for lymphoma and leukemia; CD33 for the treatment of Acute Myeloid Leukemia (NCT02944162), HER2 against glioblastoma (NCT03383978) and Mucin-1 (MUC1) in MUC1-positive relapsed or refractory solid tumor-like colorectal carcinoma (CRC) and gastric carcinoma. These and other trials are listed and summarized in Table 3. Efforts directed against multiple myeloma, with CD138 (71) and SLAMF7 (72) as main targets, are still in the preclinical phase. CAR-NK cells targeting solid tumors are now also being explored in preclinical settings. For this, NK cell-specific co-stimulatory domains are being explored to replace T-cell specific domains in an attempt to increment NK cell-specific activation. Two promising approaches target the prostate stem cell antigen (PSCA), highly expressed on primary prostate tumors and metastases (73), and the epidermal growth factor type III (EGFRvIII), expressed on glioblastoma cells, using the DNAX-metastases (73), and the epidermal growth factor type III (PSCA), highly expressed on primary prostate tumors and metastases. Recently, the NKG2D transmembrane domain has been combined with an anti-mesothelin scFv and the NK cell-stimulatory domain 2B4 and CD3ζ on the NK cell surface (78). Recently, the biotech companies Glycostem Therapeutics and Zelluna Immunotherapies announced a partnership to further develop this field.

**NK Cells With Downregulated Inhibitory Receptors**

Cancer cells can throttle immune responses by stimulating key regulators on the surface of immune effector cells known as inhibitory checkpoint molecules. Identification and targeting of inhibitory checkpoints significantly boost immune responses and is therefore of major interest in cancer immunotherapy. During *ex vivo* expansion of NK cells, some inhibitory receptors, like NKG2A, are still highly expressed (79–81), suggesting a critical role in NK cell maturation. On the other end, inhibitory receptors curb NK cell cytotoxic activity and reduce therapeutic efficacy in clinical settings. Indeed, hyporesponsive NKG2A-expressing NK cells are prominent within the TME, thus stressing the importance of this receptor in reducing NK cell activity (82). NKG2A dimerizes with CD94 to bind HLA-E molecules loaded with tumor peptides. While HLA-E surface expression in tumor cells is very weak, IFN-γ produced by NK cells can cause its overexpression (29, 50, 83). Once the peptide/HLA-E complex is stabilized and binds NKG2A, NK cell activity is dampened. In contrast, RNAi-mediated inhibition of NKG2A expression by shRNA improved NK cell *in vitro* activity against an HLA-E expressing B-lymphoblastoid cell line (53). Notably, NK cell cytotoxicity was also enhanced against the AML-derived, HLA-E-negative cell line K562. This increased HLA-E expression in the cell line further develops this field.

---

**TABLE 3 | Ongoing clinical trials with CAR-NK cells.**

| CAR Target | Condition | Study Phase | NCT    |
|------------|-----------|-------------|--------|
| CD19       | B-Lymphoid Malignancies/ALL/CLL | I/II | NCT03056339 |
| CD19/CD22  | B-Cell Lymphoma | I | NCT03824964 |
| CD19       | B-Cell Lymphoma | I | NCT03690310 |
| CD19       | ALL/CLL | I/II | NCT02892695 |
| CD19       | ALL | I | NCT00995137 |
| CD33       | AML | I/II | NCT02944162 |
| CD7        | AML/T-cell leukemia | I/II | NCT02742727 |
| CD22       | B-Cell Lymphoma | I | NCT03892767 |
| BCMA       | MM | I/II | NCT03940833 |
| HER-2      | Glioblastoma | I | NCT03383978 |
| Mesothelin | Ovarian cancer | I | NCT03892637 |
| PSMA       | Prostate cancer | I | NCT03892663 |
| ROBO1      | Pancreatic cancer | I/II | NCT03941457 |
| ROBO1      | Solid Tumors | I | NCT03941720 |
| ROBO1      | Solid Tumors | I | NCT03940820 |
| NKG2DL     | Solid Tumors | I | NCT03415100 |
| MUC1       | Solid Tumors | I | NCT02899954 |
| N.A.       | NSCLC | I | NCT03666705 |
| ACE2/NKG2DL | COVID-19 | I/II | NCT04324996 |

ALL, Acute Lymphocytic Leukemia; AML, Acute Myeloid Leukemia; CLL, Chronic Lymphocytic Leukemia; MM, Multiple Myeloma; NSCLC, Non-small Cell Lung Cancer.
independent cytotoxicity was probably caused by increased activating Nkp30 receptor levels in the NKG2A-negative cell. Unfortunately, these cells have only been tested on a small set of HLA-E positive/negative cell lines. Another group downregulated NKG2A function in PBNKs and NK-92 cells by linking an anti-NKG2A antibody to an endoplasmic reticulum-retention domain, and achieved increased cytotoxicity against both HLA-E-positive and -negative cells derived from Ewing's sarcoma, osteosarcoma and AML, as well as prolonged survival in immunodeficient mice expressing HLA-E tumors (50). Blocking of inhibitory receptors represents a feasible approach within the field of biotech industry, although the studies focused on NKG2A only, and their number so far is very limited. Additionally, data comparing NKG2A-negative NK cells and CAR-NK cell activity against the same tumor type are lacking, precluding a comparison between both strategies.

**NK Cells With Modified ADCC**

FcγRIII (CD16)-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) plays an important role in tumor clearance. The CD16 isoform expressed on NK cells (CD16a) has two allelic variants with a phenylalanine (P) or valine (V) at amino acid 158, resulting in low (CD16a-158-F/F) and high affinity (CD16a-158-V/V) Fc receptor isoforms. Several studies showed that patients expressing the CD16a-158 F/V variant have better cytotoxicity against tumor cells than patients that are either heterozygous (CD16a-158-V/F) or homozygous for V upon mAb treatment (84, 85). CD16a expression is downregulated upon NK cell activation, mainly due to matrix metalloproteases shedding (86). NK-92 cells, an attractive and cheap source for clinical applications of NK cells, cannot mediate ADCC as they lack CD16 expression. In an attempt to constitutively enhance ADCC activity of NK-92 cells, these cells have been modified to express a CD16a chimera fused to the CD28 and 4-1BB co-stimulatory domains. Expression of the construct enhanced their cytotoxic activity and restored ADCC activity against CD20-positive tumor cells (87). In another attempt, ADCC potency of NK-92 cells was improved by transduction of the high-affinity CD16a-V158 mutant that is resistant to ADAM17-mediated cleavage and shedding (88, 89). This cell line, (haNK, developed by NantKwest), showed improved killing capacity compared to PBNK cells from healthy donors and is now in clinical trials against breast cancer (NCT03387085), Merkel cell carcinoma (NCT03853317) and squamous cell carcinoma (NCT03387111). CD16a-158V expression in NK-92 and iPScs-derived NK cells led to enhanced NK cell activation in the presence of rituximab (90), as well as in PBNKs, although the studies focused on NKG2A only, and their number so far is very limited. Additionally, data comparing NKG2A-negative NK cells and CAR-NK cell activity against the same tumor type are lacking, precluding a comparison between both strategies.

**NK Cells With Increased Persistence and Proliferation Potential**

*In vivo* persistence of NK cells strictly depends on exogenous cytokines. Allogeneic NK cell survival is typically restricted to a couple of weeks, necessitating multiple infusions to achieve therapeutic effects (40). Administration of recombinant IL-2 (rIL-2) in clinical settings resulted in severe toxicities at high doses and activation of inhibitory T-reg cells at low doses (91). To circumvent these drawbacks, NK-92 cells have been transduced with the IL-2 gene, abolishing NK-92 growth dependence on exogenous IL-2 (92). Transduced NK-92 cells have been tested in nude mice with 3-day-established liver metastases, without exerting side effects after 6 months of treatment. With the discovery that IL-15 has higher potency and lower toxicity than IL-2 (93), the focus has shifted to this cytokine. IL-15 exists in both a soluble and membrane-bound isoforms complexed with IL-15 Rα (94, 95). NK cells growth dependence on IL-15 has been circumvented by retrovirally transducing PBNK cells with the mbIL-15 membrane-bound isoform, increasing *in vivo* NK cell persistence without the need for exogenous IL-2 or IL-15 (46). Stimulatory cytokine signaling has also been recently combined with CAR-NK technology. Briefly, CB-derived NK cells were transduced with a retrovirus encoding a CD19 CAR, soluble IL-15 and the iC9 suicide gene (96). These NK cells had prolonged *in vivo* survival and were able to control tumor progression significantly better than non-modified or CD19 CAR-only NK cells. The MD Anderson Cancer Centre phase I clinical study followed, as mentioned above. A CAR construct, targeting the EpCAM carcinoma antigen epithelial cell adhesion molecule, that also encoded IL-15 has been transduced into NK-92 cells (56). The IL-15 transgene induced strong proliferation signals, allowing transduced NK-92 cells to grow in the absence of stimulatory cytokines and, additionally, acting as a selection marker for the transduced cells. The CAR gene selectively improved NK cell cytotoxicity against EpCAM-expressing cell lines.

NK cells have low proliferative potential, possibly because of progressive telomere shortening during division cycles. The process can be partially overcome by overexpressing the telomerase reverse transcriptase protein (TERT) responsible for telomere end restoration, normally very lowly expressed in primary cells. Indeed, NK-cell lifespan has already been extended to several months by hTERT overexpression in PBNKs (47). However, transduced PBNKs were still not capable of autonomous growth and proliferation remained dependent on cell-to-cell contacts with feeder cells. Such “immortalized” NK cells can be useful for clinical applications, where large amounts of NK cells need to be injected, and donor availability and/or variability is limiting. Nevertheless, the use of feeder cells in clinical manufacture is not accepted by all regulatory authorities, as it might pose safety concerns for patients. Consequently, feeder cell-free culture systems need to be developed for worldwide
NK Cells With Increased Tumor Homing

Immune cell homing to and infiltration of tumors is a fundamental prerequisite for effective tumor killing. NK cell ability to infiltrate into the tumor stroma is limited, negatively affecting NK cell therapy efficacy (97). The chemokine receptor CCR7 redirects NK cells preferentially to lymph node-associated chemokine CCL19. CCR7 mRNA transfection into PBNKs by mRNA electroporation improved their in vitro migration towards CCL19 (60). Another group used primary NK cells transduced with retrovirus encoding CXCR2 to improve trafficking towards renal cell carcinoma (48). The NK-like YT cell line was transduced with lentivirus encoding an anti-EGFRvIII CAR and the chemokine receptor CXCR4 (75). The CXCR4 receptor promoted specific chemotaxis to glioblastoma cells secreting the CXCL12/SDF-1α chemokine, while the αEGFRvIII-CAR improved the killing specificity and cytotoxicity. The approach also increased tumor regression and survival in xenograft mouse models.

These studies, although limited and mainly in vitro, demonstrate that NK cell homing to specific tumor sites can improve NK cell-mediated tumor clearance, especially if combined with strategies to enhance NK cell functions after migration to the tumor site.

NK Cells With Increased Resistance to the Tumor Microenvironment

One of the major immunosuppressive factors within the TME is TGF-β, produced by various stromal cells, T-reg, MDCs, and the tumor cells. TGF-β interferes with NK cell activation by counteracting several important activating receptors. It downregulates NK cell NKG2D and Nkp30 surface expression (98, 99) and inhibits CD16-mediated IFN-γ production and ADCC in vitro (100). RNAi-mediated knockdown of SMAD3, a TGF-β receptor signal transducer, by transduction of NK-92 cells with a lentivirus encoding SMAD3 shRNA increased IFN-γ, perforin and granzyme B expression, and enhanced cytotoxicity, increasing tolerance to TGF-β signaling both in vitro and in vivo (101). Expression of a chimera consisting of the TGF-β receptor type II (TGFBR2) extracellular and transmembrane domain fused to the NKG2D intracellular domain on NK-92 cells caused tolerance to the TGF-β signaling and improved chemoattraction to TGF-β-secreting tumor cell lines (102). Additionally, these NK-92 cells inhibited naïve CD4+ T cell to T-reg differentiation by IFN-γ signaling. A dominant-negative mutant form of TGFBR2 (DNRII) has been expressed in CB-derived NK cells to block or decrease TGF-β signaling. These NK cells did not show downregulation of activating receptors NKG2D and DNAM-1 or of granzyme B and perforin upon TGF-β stimulation (51). The same group further created an improved version of the DNRII receptor (renamed “NKA” receptor) by fusing its extracellular domain to DAP12, providing NK cell activating signals upon TGF-β stimulation. CB-derived NK cells expressing NKA had enhanced cell cytotoxic activity and persistence against neuroblastoma both in vitro and in vivo (52). A similar approach with the DNRTβII receptor in NK-92 cells increased their resistance to TGF-β signaling, potentiating antitumor activity in an in vivo lung cancer murine model (63).

Adenosine is emerging as another key negative regulator of NK cells within the TME. Adenosine signals via the A2AR receptor and limits NK cell maturation, negatively affecting their proliferation and tumor control (35). Blockage of A2AR with an inhibitor caused anti-metastatic effects in breast cancer and melanoma mouse models (103). mAb-mediated inhibition of CD73 ecotnucleotidase, one of the key enzymes responsible for extracellular adenosine synthesis, in combination with NKG2D CAR NK-92 cells generated using a PiggyBac transposon system, improved control of CD73-positive tumors (64). The combinatorial approach has been tested against cell lines of prostate cancer (PC3), lung carcinoma (A549) and glioblastoma (GBM43 and GBM10) expressing high levels of CD73 and a xenograft mouse model of lung carcinoma with A549 cells. Although the mAb-CAR combined approach did not dramatically improve anti-tumor activity of the NK-92 cells, the study is important as a first demonstration that stable CAR integration with a non-viral system in NK cells is feasible, and can be extended to other constructs.

FUTURE PERSPECTIVES AND CONCLUDING REMARKS

NK cell trials have been ongoing for several years by now, demonstrating the safety and efficacy of NK cell-based immunotherapies, especially against hematological malignancies. So far, efficacy against solid tumors is limited, and requires additional technology. NK cells were quite refractory to standard genetic manipulation techniques, resulting in major delays of the first clinical trials with genetically engineered NK cell. Substantial improvements in the last years has led to the first trials. Nonetheless, challenges remain. Viral-based genetic manipulation of NK cells is currently the gold standard to stably express exogenous genes, but transduction efficiency and transgene expression levels are still variable, requiring multiple transductions rounds or post-transduction enrichment. Besides, insertional mutagenesis needs continued safety monitoring. Non-viral delivery methods are still far from routine implementation, as the efficiency and viability can be very low, and the transgene expression can be transient. Low efficiencies are not a great disadvantage with immortalized cells like NK-92, as these can be enriched and then grown indefinitely. But ex vivo expanded NK cells have a limited proliferation potential and enter senescence relatively soon (47). For these cells, highly effective engineering strategies are much more important.

As mentioned above, NK cell efficacy against solid tumors is limited compared to hematological malignancies. Introduction of CAR constructs into NK cells, restoring ADCC functions and/or downregulation of inhibitory receptors can dramatically
potentiate their effector functions, helping the patient’s immune system in eradicating the disease. The need for NK-specific CAR constructs is now widely recognized, as T-cell-based CARs have reduced activation potentials compared to the former ones, and high-throughput screening techniques will be essential for their identification (66). The limited proliferation potential of NK cells usually does not allow them to persist longer than 2–3 weeks after injection in vivo. Furthermore, homing to tumor sites is often hampered by the TME. Consequently, a highly cytotoxic potential could be relatively limited if NK cells do not persist long enough to eradicate malignant cells or home in on tumor sites. Early efforts in providing NK cells with stimulatory cytokines prolonging half-life like IL-15 are encouraging and worth being further developed, especially in combination with CARs or other activating receptors. Similarly, increasing expression of chemokine receptors on the NK cell surface improves NK cells targeted trafficking and tumor eradication, paving the way for combinatorial strategies. Many solid tumors are difficult to target also because they are encapsulated and protected by a thick layer of extracellular matrix (ECM), a mesh made up mainly by insoluble proteins like type IV collagen and heparan sulphate proteoglycans (HSPGs), that reduce the infiltration abilities of NK cells (104). Heparanase is upregulated in activated NK cells, improving migration within tumor stroma and playing an important role in reducing tumor growth and metastases (104). To conclude, understanding NK cell biology is another key factor that will help to improve genetic engineering strategies and overcome tumor resistance mechanisms, and allow to fully unleash anti-cancer NK cell potential.

AUTHOR CONTRIBUTIONS

SM wrote the paper. LK, DG, and JS reviewed the paper. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by a network grant of the European Commission (H2020-MSC-ITN-765104-MATURE-NK) to Glycistem Therapeutics and SM was a fellow in the project, and by a joint grant of the European Commission and EUREKA (E11764 MODIFY-NK) to Glycistem Therapeutics.
21. Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. *Nature reviews. Drug Discovery* (2020) 19(3):200–18. doi: 10.1038/s41573-019-0055-2

22. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer and dendritic cells. *J Exp Med* (2002) 195(3):327–33. doi: 10.1084/jem.20010938

23. Vitale M, Della Chiesa M, Carlomagno S, Pende D, Arico M, Moretta L, et al. NK-dependent DC maturation is mediated by TNFalpha and IFNGamma released upon engagement of the NKp30 triggering receptor. *Blood* (2005) 106(2):566–71. doi: 10.1182/blood-2004-10-0435

24. Wehrer R, Lobel B, Bornhauser M, Schakel K, Cartellieri M, Bachmann M, et al. Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells. *Int J Cancer* (2009) 124(2):358–66. doi: 10.1002/ijc.23962

25. Hanna NBR. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. *Immuno Invest* (1981) 127(5):1754–8.

26. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, et al. Prognostic significance of tumor infiltrating natural killer cell subsets CD57 in patients with squamous cell lung cancer. *Lung Cancer* (2002) 35(1):23–8. doi: 10.1016/s1050-3273(01)00292-6

27. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. *Cancer* (1997) 97(12):2320–3. doi: 10.1002/cncr.1977097122320:aid-cnccr3.3.02-c

28. Nayar G, Chu Y, Cairo MS. Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. *Front Oncol* (2019) 9:5151. doi: 10.3389/fonc.2019.00551

29. Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. *Oncogenesis* (2018) 7(1):10. doi: 10.1038/s41389-017-0011-9

30. Siemens DR, Hu N, Sheikhi AK, Chung E, Frederiksen LJ, Pross H, et al. *Cancer Res* (10):1515–21. doi: 10.1158/0008-5472.CAN-08-0054

31. Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Rouce RH, Shaim H, Sekine T, Weber G, Ballard B, Ku S, et al. The TGF- 

32. Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. *Oncogenesis* (2018) 7(1):10. doi: 10.1038/s41389-017-0011-9

33. Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. *Oncogenesis* (2018) 7(1):10. doi: 10.1038/s41389-017-0011-9

34. Chambers AM, Matosevic S. Immunometabolic Dysfunction of Natural Killer Cells for cancer immunotherapy. *Cancer Res* (2011) 35(1):23–8. doi: 10.1038/leu.2015.327

35. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. *Oncogenesis* (2018) 7(1):10. doi: 10.1038/s41389-017-0011-9

36. Chambers AM, Matosevic S. Immunometabolic Dysfunction of Natural Killer Cells for cancer immunotherapy. *Cancer Res* (2011) 35(1):23–8. doi: 10.1038/leu.2015.327

37. Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D. Replicative potential of human natural killer cells. *Br J Haematol* (2009) 145(3):666–13. doi: 10.1111/j.1365-2457.2009.06766.x

38. Kremer V, Ligtenberg MA, Zendebsdel R, Seitz C, Duivenvoorden A, Wennerberg E, et al. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. *J Immunother Cancer* (2017) 5(1):73. doi: 10.1186/s40425-017-0275-9

39. Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKGD2 specificity enhances natural killer cell activation and killing of tumor cells. *Cancer Res* (2013) 73(6):1777–86. doi: 10.1158/0008-5472.CAN-12-3558

40. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNeary SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. *Blood* (2005) 105(8):3051–7. doi: 10.1182/blood-2004-07-2974

41. Yoon SR, Lee YS, Yang SH, Ahn KH, Lee JH, Lee JH, et al. Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. *Bone Marrow Transplant* (2010) 45(6):1038–46. doi: 10.1038/bmt.2009.304

42. Muller S, Bexte T, Gebel V, Kalensere F, Stolzenberg E, Hartmann J, et al. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia. *Front Immunol* (2019) 10:3123. doi: 10.3389/fimmu.2019.03123

43. Sutlu T, Nystrom S, Gilljam M, Stellan B, Applequist SE, Alici E. Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. *Hum Gene Ther* (2012) 23(10):1090–100. doi: 10.1089/hum.2012.080

44. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. *Blood* (2005) 106(1):576–83. doi: 10.1182/blood-2004-12-4797

45. Altavera B, Landmeier S, Pichere S, Temme J, Schweer K, Kallayangiri S, et al. CD28 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. *Clin Cancer Res* (2009) 15(15):4857–66. doi: 10.1158/1078-0432.CCR-08-2810

46. Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SM, Coustan-Smith E, et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. *Blood* (2014) 124(7):1081–8. doi: 10.1182/blood-2014-05-556837

47. Fujiyaki H, Kakuda H, Imai C, Mullighan CG, Campana D. Replicative potential of human natural killer cells. *Br J Haematol* (2009) 145(5):666–13. doi: 10.1111/j.1365-2411.2009.06766.x

48. Kremer V, Ligtenberg MA, Zendebsdel R, Seitz C, Duivenvoorden A, Wennerberg E, et al. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. *J Immunother Cancer* (2017) 5(1):73. doi: 10.1186/s40425-017-0275-9

49. Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKGD2 specificity enhances natural killer cell activation and killing of tumor cells. *Cancer Res* (2013) 73(6):1777–86. doi: 10.1158/0008-5472.CAN-12-3558

50. Manetto et al. Genetic Engineering of NK Cells
Mantesso et al. | Genetic Engineering of NK Cells

60. Carlsten M, Levy E, Karambelkar A, Li L, Reger R, Berg M, et al. Engineering NK Cells Modified With an EGFR<sup>VIII</sup>-Specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1alpha-secreting Glioblastoma. *Immunother* (2015) 38 (5):97–210. doi: 10.1097/CJII.0000000000000882

61. Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKGD2-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. *Nat Immunol* (2006) 7(5):524–32. doi: 10.1038/ni1325

62. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, et al. An activating immunoreceptor complex formed by NKGD2 and DAP10. *Science* (1999) 285(5428):730–2. doi: 10.1126/science.285.5428.730

63. Walseng E, Koksal H, Sektogla IM, Fane A, Skorstad G, Kvalheim G, et al. A TCR-based Chimeric Antigen Receptor. *Sci Rep* (2017) 7(1):10713. doi: 10.1038/s41598-017-11126-y

64. Spanholtz J, Tordo M, Eissens D, Preijers F, van der Meer A, Joosten I, et al. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. *PloS One* (2010) 5(2):e9221. doi: 10.1371/journal.pone.0009922

65. Denman CJ, Senyavuk VV, Somanschi SS, Phatarpekar PV, Korp LM, Johnson JL, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. *PloS One* (2012) 7(1):e30264. doi: 10.1371/journal.pone.0030264

66. Oyer JL, Igarashi RY, Kulikowski AR, Colosimo DA, Solt MM, Zakari A, et al. Generation of highly cytotoxic natural killer cells for treatment of acute myelogenous leukemia using a feeder-free, particle-based approach. *Biol Blood Marrow Transplant* (2015) 21(4):632–9. doi: 10.1016/j.bbmt.2014.12.037

67. Mammessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquier M, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. *J Clin Invest* (2011) 121(9):3669–22. doi: 10.1172/JCI45816

68. Marin D, Ruiz-Cabello F, Pedranić S, Mendez R, Jimenez P, Geraghty DE, et al. Analysis of HLA-E expression in human tumors. *Immunogenetics* (2003) 54(11):767–75. doi: 10.1007/s00251-002-0526-9

69. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIa gene. *Blood* (2002) 99(3):754–8. doi: 10.1182/blood.v99.3.754.734

70. Weng WK, Ley R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. *J Clin Oncol* (2003) 21(12):3940–7. doi: 10.1200/JCO.2003.05.013

71. Grzywacz B, Kataria N, Verneris MR. CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. *Leukemia* (2007) 21(2):356–9; author reply 9. doi: 10.1038/sj.leu.2404499

72. Chen Y, You F, Jiang L, Li J, Zhu X, Bao Y, et al. Gene-modified NK-92 cell therapy. *Immunotherapy* (2015) 194(7):3201–12. doi: 10.4049/immunother.1400330

73. Muller N, Michen S, Tietze S, Topfer K, Schulte A, Lamszus K, et al. Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, hANK. *JCI Insight* (2019) 4(20):e13068. doi: 10.1172/jci.insight.130688

74. Jing Y, Ni Z, Wu J, Higgins L, Markowski TW, Kauffman DS, et al. Identification of an ADAM17 cleavage region in human CD16 (FcgammaRIIa) and the engineering of a non-cleavable version of the receptor in NK cells. *PloS One* (2015) 10(3):e0121788. doi: 10.1371/journal.pone.0121788

75. Ito S, Bollard CM, Carlsten M, Melenhorst JJ, Biancotto A, Wang E, et al. Ultra-low dose interleukin-2 promotes immune-modulating function of...
92. Nagashima S, Maillard R, Kashi Y, Reichert TE, Herberman RB, Robbins P, et al. Stable Transduction of the Interleukin-2 Gene Into Human Natural Killer Cell Lines and Their Phenotypic and Functional Characterization In Vitro and In Vivo. *Blood* (1998) 91(10):3850–61. doi: 10.1182/blood.V91.10.3850
93. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. *J Clin Oncol* (2015) 33(1):74–82. doi: 10.1200/JCO.2014.57.3329
94. Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. *J Exp Med* (2004) 200(7):825–34. doi: 10.1084/jem.20041389
95. Bergamaschi C, Rosati M, Jalal R, Valentin A, Kulkarni V, Alicea C, et al. Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. *J Biol Chem* (2008) 283(7):4189–99. doi: 10.1074/jbc.M705725200
96. Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. *Leukemia* (2018) 32(2):520–31. doi: 10.1038/leu.2017.226
97. Halama N, Braun M, Kahler C, Spille A, Quack C, Rahbari N, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. *Clin Cancer Res* (2011) 17(4):678–89. doi: 10.1158/1078-0432.CCR-10-2173
98. Ghiringhelli F, Menard C, Termé M, Flamant C, Taieb J, Chaput N, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. *J Exp Med* (2005) 202 (8):1075–83. doi: 10.1084/jem.20051511
99. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. *J Immunol* (2004) 172(12):7335–40. doi: 10.4049/jimmunol.172.12.7335
100. Trotta R, Dai Col J, Yu J, Ciarlariello D, Thomas B, Zhang X, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. *J Immunol* (2008) 181(6):3784–92. doi: 10.4049/jimmunol.181.6.3784
101. Wang QM, Tang PM, Lian GY, Li C, Li J, Huang XR, et al. Enhanced Cancer Immunotherapy with Smad3-Silenced NK-92 Cells. *Cancer Immunol Res* (2018) 6(8):965–77. doi: 10.1158/2326-6066.CIR-17-0491
102. Wang Z, Guo L, Song Y, Zhang Y, Lin D, Hu B, et al. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-betaR II and NKG2D. *Cancer Immunol Immunother* (2017) 66(4):537–48. doi: 10.1007/s00262-017-1959-1
103. Mittal D, Young A, Stannard K, Yong M, Teng MW, Allard B, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. *Cancer Res* (2014) 74(14):3652–8. doi: 10.1158/0008-5472.CAN-14-0957
104. Putz EM, Mayfosh AJ, Kos K, Barkauskas DS, Nakamura K, Town L, et al. NK cell heparanase controls tumor invasion and immune surveillance. *J Clin Invest* (2017) 127(7):2777–88. doi: 10.1172/JCI92958

**Conflict of Interest:** SM, DG, JP and LH are employed by Glycostem Therapeutics.